IDH1/2 mutations are commonly found in adult gliomas. Gliomas with these mutations are thought to have a better prognosis than patients without the IDH1/2 mutations, but nearly all patients will eventually recur, and thus better options are needed. A recent discovery was made that IDH1/2 mutations induce a “BRCAness” state. As a result, this makes them sensitive to a class of drugs known as PARP inhibitors. This phase I/II study will assess the safety and overall response rate of pamiparib, a potent PARP inhibitor, in combination with temozolomide, a chemotherapy utilized in neurological cancer, in patients with recurrent IDH1/2 mutated gliomas.
Trial Registration: ClinicalTrials.gov Identifier: NCT03914742